Adaptate Biotherapeutics
Adaptate Biotherapeutics is a private Canadian biotech founded in 2019 that develops antibody-based therapeutics designed to modulate gamma delta T cells in situ for the treatment of disease.
- Company typePrivate
- Founded2019
- HeadquartersLondon, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Adaptate Biotherapeutics does
Adaptate Biotherapeutics is a privately held Canadian biotherapeutics company founded in 2019, headquartered in London, Ontario, with a workforce of 11–50 employees. The company is focused on developing antibody-based therapeutics that modulate gamma delta T cells in situ — that is, directly within the patient's body — as a treatment modality. This places Adaptate within the niche of immuno-oncology and immunology drug development, where gamma delta T cells have attracted increasing scientific interest due to their role in bridging innate and adaptive immune responses. The company's differentiation lies in its antibody-based mechanism of action targeting gamma delta T cells in their native tissue context, rather than ex vivo cell engineering approaches pursued by some peers.
The underlying technology is a proprietary antibody discovery and engineering platform directed at gamma delta T cell biology. As with most companies at this stage, Adaptate's outputs would be therapeutic antibody candidates intended for indications in oncology, infectious disease, or inflammatory disorders where gamma delta T cell modulation has therapeutic rationale, though specific programs and target indications are not enumerated in the provided data. The company has named Stewart Kay as its Chief Business Officer (CBO), a role typical of an early-stage biotech responsible for capital formation, business development, and partnership strategy.
Adaptate's business model, as inferred from its stage and structure, is consistent with a venture-backed pre-clinical or early-clinical biotech. Revenue is not disclosed, and no commercial products or licensing deals are described in the input. The company's economics are likely to be driven by future out-licensing, partnership, or co-development agreements with larger pharmaceutical companies, a thesis supported by Takeda Ventures' participation in the company's 2021 funding round alongside Abingworth. This suggests a development-partner commercialization model rather than independent product launch.
Adaptate Biotherapeutics firmographics
Firmographics- Name
- Adaptate Biotherapeutics
- Website
- https://adaptate.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Adaptate Biotherapeutics is a private Canadian biotech founded in 2019 that develops antibody-based therapeutics designed to modulate gamma delta T cells in situ for the treatment of disease.
- Ownership category
- akta.pro rank
Adaptate Biotherapeutics industry classification
Industry- Product category
- Antibody Biotherapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
Keywords
Where Adaptate Biotherapeutics is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Adaptate Biotherapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain
Adaptate Biotherapeutics product offering
Product offeringCore offering
Adaptate Biotherapeutics is a biotherapeutics company that develops antibodies designed to modulate gamma delta (γδ) T cells in situ. The company's core activity is the discovery and development of antibody-based therapeutic candidates targeting γδ T cell biology for immuno-oncology applications. Its pipeline is intended for advancement through partnership, licensing, or further clinical development with larger pharmaceutical entities.
Differentiator
Problem solved
Functional benefit
Companies that use Adaptate Biotherapeutics
Customer profileIdeal customer profiles1 record
Adaptate Biotherapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Adaptate Biotherapeutics partnerships and signals
Strategic signalScale indicators1 record
Recent moves3 records
Expansion highlights2 records
Adaptate Biotherapeutics competitors and assessment
Company assessmentDirect peers
- Lava Therapeutics: Lava Therapeutics develops bispecific gamma delta T-cell engagers for cancer, the closest direct mechanistic peer to Adaptate's antibodies that modulate gamma delta T cells in situ.
- Innate Pharma: Innate Pharma is a clinical-stage immunology company with multiple gamma delta T-cell programs (e.g., IPH61, innate cell engagers), directly comparable in target biology and immuno-oncology focus.
- Adaptimmune: Adaptimmune develops TCR-based cell therapies for solid tumors; comparable in T-cell-targeted oncology strategy even though Adaptate uses antibodies rather than engineered cells.
Emerging players
- GammaDelta Therapeutics: GammaDelta Therapeutics is the original academic spin-out that founded the gamma delta T-cell platform space; comparable as the progenitor peer in the same target biology that Adaptate also pursues.
- Adagene: Adagene is an antibody discovery and engineering platform company developing precision immuno-oncology biologics, comparable in antibody modality and oncology indication focus.
- Shattuck Labs: Shattuck Labs is a clinical-stage immunotherapy company working on immune cell-engaging bispecifics, an adjacent antibody-based immuno-oncology peer pursuing similar tumor-infiltrating lymphocyte biology.
- Janux Therapeutics: Janux Therapeutics develops T-cell engager antibody therapeutics for oncology, overlapping with Adaptate in the strategy of recruiting/modulating T cells via antibody biologics.
- Compugen: Compugen is a computational immunology company developing antibody-based immuno-oncology therapeutics against novel targets, comparable as an antibody-platform oncology biotech.
- Macrogenics: MacroGenics develops immuno-oncology antibody therapeutics (DART and bispecific platforms), an adjacent antibody-platform oncology peer addressing similar T-cell-engagement mechanisms.
Broad incumbents
- Allogene Therapeutics: Allogene is an allogeneic CAR-T leader targeting multiple T-cell-driven oncology indications; a broader incumbent peer in the T-cell-based cancer immunotherapy category where Adaptate also competes for partnership capital.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Adaptate Biotherapeutics social profiles
Digital presenceAdaptate Biotherapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Adaptate Biotherapeutics leadership team
Management profileNumber of profiles
Profiles1 record
Adaptate Biotherapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Adaptate Biotherapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Adaptate Biotherapeutics
What does Adaptate Biotherapeutics do?
Adaptate Biotherapeutics is a biotherapeutics company that develops antibodies designed to modulate gamma delta (γδ) T cells in situ. The company's core activity is the discovery and development of antibody-based therapeutic candidates targeting γδ T cell biology for immuno-oncology applications. Its pipeline is intended for advancement through partnership, licensing, or further clinical development with larger pharmaceutical entities.
When was Adaptate Biotherapeutics founded?
Adaptate Biotherapeutics was founded in 2019. It employs 11 to 50 people.
Where is Adaptate Biotherapeutics based?
Adaptate Biotherapeutics is headquartered in London, Canada, in the North America region.
Who are Adaptate Biotherapeutics's main competitors?
Direct peers on record are Lava Therapeutics, Innate Pharma and Adaptimmune. Emerging players are GammaDelta Therapeutics, Adagene, Shattuck Labs, Janux Therapeutics, Compugen and Macrogenics. Allogene Therapeutics is listed as a broad incumbent.
Does Adaptate Biotherapeutics have an API?
No public API is recorded for Adaptate Biotherapeutics.
What industry is Adaptate Biotherapeutics in?
Adaptate Biotherapeutics's product category is Antibody Biotherapeutics. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2836.